Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
The introduction of atypical antipsychotics into clinical practice has lead to an increase of adverse metabolic effects in psychotic patients. Amisulpride is a substituted benzamide derivative, and its use is associated with a lower risk of weight gain compared to other atypical antipsychotics. The case of an acute and excessive weight increase in a female first-episode schizophrenic patient who was treated with amisulpride monotherapy is reported. The improvement in psychopathology was remarkable. However, the patient gained 12.9 kg of body weight in the first 2 months of amisulpride administration and a total of 17.3 kg, 6 months after initiation of the treatment. Glucose and insulin levels, as well as a glucose tolerance test, remained normal throughout the observation period.
Papadimitriou
George N
GN
Department of Psychiatry, Athens University Medical School, Eginition Hospital, Athens, Greece. gnpapad@med.uoa.gr
Theleritis
Christos G
CG
Dikeos
Dimitris G
DG
Psarros
Constantin J
CJ
Soldatos
Constantin R
CR
D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride